New medicines in the pipeline can extend lives, save money, and even help prevent disease before symptoms appear - if we don't discourage their innovators and investors by trying to lower drug prices artificially. Unlocking Precision Medicine explores the environment necessary for creation of these health care game-changers, and explains how the marketplace can effectively make them more affordable to all without killing the golden goose.
About the Author
Paul Howard is a senior fellow at the Manhattan Institute and director of health policy. Howard was part of the health care policy advisory group for Mitt Romney's 2012 presidential campaign, has testified twice before Congress, and serves on a panel of judges for Celgene's Innovation Impact Awards. He is a contributor to The Apothecary, the Forbes blog on health care policy and entitlement reform, and a regular columnist for The Morning Consult. Peter Huber is a senior fellow at the Manhattan Institute, where he writes on drug development, energy, technology, and the law. His most recent full length book is The Cure in the Code: How 20th Century Law Is Undermining 21st Century Medicine. Before joining MI, Huber was an associate professor at MIT. He clerked on the D.C. Circuit Court of Appeals for Ruth Bader Ginsburg and on the U.S. Supreme Court for Sandra Day O'Connor.